Harrow Expands VEVYE Access for All Program, Offering $59 FDA-Approved Dry Eye Treatment

FDA-approved dry eye relief—no hurdles, no headaches, just $59 a bottle with VEVYE Access for All. 

On April 10, 2025, Harrow (Tennessee, USA) announced an expansion of its VEVYE Access for All (VAFA) program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product manufactured by ImprimisRx (Tennessee, USA), Harrow’s compounding subsidiary.

Beginning immediately, more than 25,000 patients across the United States will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA-approved eye drop treatment for dry eye disease, for $59 per bottle, including refills.

READ MORE: Dr. Mahnia Madan’s Four-Step Approach to Managing DED

“We are pleased to make VEVYE accessible and affordable to Klarity-C patients,” said Mark L. Baum, chief executive officer of Harrow, in a news release. “The secret to the success of VEVYE Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy. The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing VEVYE is an absolute no‑brainer.”

The VEVYE Access for All program, launched on March 17, 2025, aims to simplify dry eye therapy by eliminating barriers such as prior authorization and reimbursement delays, providing free home delivery, and offering a money-back guarantee. The program allows patients to use their insurance coverage or take advantage of Harrow’s cash price.

READ MORE: Tailoring Dry Eye Solutions 

As part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer prescriptions to PhilRx in a process designed to take less than five minutes.

“Pharmaceutical companies have long made promises to tackle the access barriers my colleagues and I encounter when advocating for our patients—especially in the realm of dry eye treatments. Harrow, a company that has consistently brought meaningful innovation to my practice, has delivered once again with VEVYE Access For All,” said Dr. Alice Epitropoulos, partner and co-founder of the Eye Center of Columbus. “I often prescribed Klarity-C because it provided exceptional value to my patients, particularly those without insurance or with limited coverage. Now, being able to offer VEVYE at that same affordable price point to some of my dry eye disease patients—without the usual insurance hassles—is a game changer. This is true price transparency and accessibility that simplifies care and supports what matters most: better outcomes.”

Dr. Mitchell Jackson, founder and medical director of Jacksoneye, added, “The value proposition here is undeniable. My colleagues in ophthalmology and optometry already know about VEVYE’s extraordinary clinical benefits. But how often do we see a pharmaceutical company actually lower costs and pass those savings directly to the patients—all while removing the insurance hurdles that have burdened our practices? Only Harrow. No prior authorizations or step therapy requirements, no surprise bills – just straightforward, reliable access to an excellent medication. It’s the kind of model our healthcare system should be moving toward.”

READ MORE: Bridging the Co-Management Gap

Klarity-C prescribers who have questions regarding the transition to VEVYE or the VEVYE Access for All program may call (855) 977-0975 or email mdsupport@usephil.com for assistance.